In a phase I trial, University of Colorado Cancer Center oncologist, Sapna Patel, MD, reported that two-thirds of patients with advanced uveal melanoma responded to a single infusion of the investigational T-cell therapy anzu-cel, marking a potential breakthrough for a cancer with few effective treatments.